GlassScriptPhysician profile
Mitchell K Rosen
NPI 1730278458
$7,879.62
in general payments reported to CMS, 2019-2025
36 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $795 · 2021: $1,259 · 2022: $929 · 2023: $1,393 · 2024: $987 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,249.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,022.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $937.94 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $576.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $426.83 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $409.03 | 2019-2022 | |
| Lilly USA, LLC | $396.14 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $309.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.73 | 2020-2023 | Stiolto Respimat |
| Amarin Pharma, INC. | $245.69 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $244.54 | 2019-2021 | |
| Exact Sciences Corporation | $233.34 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $175.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.39 | 2020-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $168.18 | 2019-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.